Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
2 "Ruth Navarro-Artieda"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Response
Original Article
Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients
Antoni Sicras-Mainar, Ruth Navarro-Artieda
Diabetes Metab J. 2015;39(1):74-81.   Published online February 16, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.1.74
  • 3,689 View
  • 27 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   
Background

To evaluate resource use and health costs due to the combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and renal impairment in routine clinical practice.

Methods

An observational, retrospective study was performed. Patients aged ≥30 years treated with metformin who initiated a second oral antidiabetic treatment in 2009 to 2010 were included. Two groups of patients were analysed: metformin+DPP-4 inhibitors and other oral antidiabetics. The main measures were: compliance, persistence, metabolic control (glycosylated hemoglobin< 7%) and complications (hypoglycemia, cardiovascular events) and total costs. Patients were followed up for 2 years.

Results

We included 395 patients, mean age 70.2 years, 56.5% male: 135 patients received metformin+DPP-4 inhibitors and 260 patients received metformin+other oral antidiabetics. Patients receiving DPP-4 inhibitors showed better compliance (66.0% vs. 60.1%), persistence (57.6% vs. 50.0%), and metabolic control (63.9% vs. 57.3%), respectively, compared with those receiving other oral antidiabetics (P<0.05), and also had a lower rate of hypoglycemia (20.0% vs. 47.7%) and lower total costs (€ 2,486 vs. € 3,002), P=0.001.

Conclusion

Despite the limitations of the study, patients with renal impairment treated with DPP-4 inhibitors had better metabolic control, lower rates (association) of hypoglycaemia, and lower health costs for the Spanish national health system.

Citations

Citations to this article as recorded by  
  • Characteristics of Hypoglycemia Pateints Visiting the Emergency Department of a University Hospital
    Sang-Hyeon Choi, Deok-Ki Youn, Moon-Gi Choi, Ohk-Hyun Ryu
    The Journal of Korean Diabetes.2016; 17(3): 202.     CrossRef
  • Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J2015;39:74-81)
    Antoni Sicras-Mainar, Ruth Navarro-Artieda
    Diabetes & Metabolism Journal.2015; 39(2): 173.     CrossRef
  • Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
    Wellington Santana da Silva Júnior, Amélio Fernando de Godoy-Matos, Luiz Guilherme Kraemer-Aguiar
    BioMed Research International.2015; 2015: 1.     CrossRef
  • Letter: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J2015;39:74-81)
    Hannah Seok
    Diabetes & Metabolism Journal.2015; 39(2): 171.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer